中基健康(000972) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥4,233,801.45, a decrease of 90.15% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of ¥8,548,581.94, with a year-to-date loss of ¥54,849,067.67, representing a 30.35% increase in losses year-on-year[4] - Total operating revenue for the period was CNY 7,359,465.17, a decrease of 83.93% compared to CNY 45,786,377.20 in the previous period[20] - The net profit for Q3 2021 was a loss of CNY 54,876,089.09, compared to a loss of CNY 42,112,313.51 in the previous year, reflecting a worsening financial position[22] - The total comprehensive income for the period was a loss of CNY 54,876,089.09, compared to a loss of CNY 42,112,313.51 in the same quarter last year[22] - Basic and diluted earnings per share were both reported at CNY -0.0711, compared to CNY -0.0546 in the previous year[22] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was -¥260,820,543.21, an increase of 8,900.39% compared to the previous year[4] - Cash received from operating activities decreased by 75.85% to ¥12,072,906.77 compared to the previous year[8] - The cash flow from operating activities showed a net outflow of CNY 260,820,543.21, compared to a smaller outflow of CNY 2,897,879.20 in the same quarter last year[25] - The company reported a cash inflow from financing activities of CNY 275,587,666.68, a significant increase from a cash outflow of CNY 48,005,077.36 in the previous year[26] - The company’s cash and cash equivalents at the end of the period totaled CNY 50,547,571.13, an increase from CNY 26,646,992.28 at the end of the previous year[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥863,303,440.02, an increase of 48.21% from the end of the previous year[4] - The company reported a total liability of CNY 736,968,339.48, compared to CNY 401,294,652.22 in the previous year[18] - Current assets totaled CNY 534,939,116.31, significantly up from CNY 221,293,424.01 at the end of 2020[16] - Total current liabilities rose to CNY 583,356,969.11 from CNY 245,683,431.85[18] - The company's equity attributable to shareholders decreased by 31.16% to ¥121,194,771.79 compared to the end of the previous year[4] - The company’s equity attributable to shareholders decreased to CNY 121,194,771.79 from CNY 176,043,839.46[18] Shareholder Information - The company had a total of 30,017 common shareholders at the end of the reporting period[10] - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., Ltd., holds 16.18% of the shares[10] Research and Development - Research and development expenses were reduced to ¥0.00 from ¥11,721,700.00 in the previous year, indicating a 100% decrease[7] - The company did not report any research and development expenses in Q3 2021, compared to CNY 11,721,700.00 in the same period last year[21] Operational Changes - The company reported a significant increase in accounts payable, which rose by 139.16% to ¥77,658,590.11 due to the resumption of production[7] - The total operating costs amounted to CNY 54,662,671.06, with operating costs specifically at CNY 7,873,335.63, down from CNY 17,470,147.34 year-over-year[21] - The company’s management expenses rose to CNY 40,941,641.91, up from CNY 36,853,759.11 year-over-year[21] - Inventory reached CNY 290,514,718.50, indicating a new addition as there was no inventory reported in the previous period[16] Legal and Regulatory Issues - The company is facing a court-ordered freeze on dividends amounting to CNY 123,970,926.36 for a period of three years[12]